BEVESPI AEROSPHERE™ approved by the US FDA for patients with COPD
April 29, 2016 |
WASHINGTON, D.C. - April 29, 2016 - AstraZeneca today announced that the US Food and Drug Administration has approved BEVESPI AEROSPHERE (glycopyrrolate and formoterol fumarate) inhalation aerosol indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. BEVESPI AEROSPHERE is not indicated to treat asthma or for the relief of acute bronchospasm. It is the only long acting dual bronchodilator delivered through a pressurized metered-dose inhaler (pMDI) and first product to use AstraZeneca’s patented Co-Suspension Technology.
To read more, please click here.